upcyte head welcome

Posters

 

Posters of upcyte technologies GmbH

  • No. 1: upcyte® hepatocytes - proliferating and metabolic competent human hepatocytes (Eurotox 2015 )pdf
  • No. 2: Generation of proliferating human hepatocytes with enhanced CYP enzyme activities (ISSX 2015)pdf
  • No. 3: Toxicology testing using upcyte® hepatocytes (ISSX 2015)pdf
  • No. 4: Use of upcyte® hepatocytes to predict toxicological outcomes (SOT 2016)pdf
  • No. 5: Metabolic competent expandable upcyte® hepatocytes enable metabolism studies including CYP2D6 dependent pathways (SOT 2016)pdf
  • No. 6: Generation of proliferating human liver sinusoidal endothelial cells (ISSX 2016) pdf
  • No. 7: Liver organoid formation using differentiated human upcyte® cells (Dechema 3D 2016)pdf
  • No. 9: Characterization of proliferating hepatocytes as a model system for drug interaction studies and toxicity screenings (Eurotox 2016)pdf
  • No. 10: Generation of proliferating human liver sinusoidal endothelial cells (upcyte® LSECs) and upcyte® hepatocytes (Eurotox 2016)pdf
  • No. 11: Generation of expanded primary human cells in large quantities for cell-based screenings (SLAS 2017)pdf
  • No. 12: Generation of expanded primary hepatocytes in large quantities for for cell based toxicity & metabolism screenings (SLAS/SOT 2017)pdf
  • No. 13: Detection of cytokeratin 18 in proliferating, primary-like upcyte® hepatocytes to predict drug-induced hepatotoxicity (SOT 2017)pdf
  • No. 14: Use of upcyte® hepatocytes as a steatosis model on a multi-organ-chip (SOT 2017)pdf
  • No. 15: Generation of expanded primary human cells (upcyte®) in large quantities for cell-based screenings (European ISSX 2017)pdf
  • No. 16: Driving primary liver cells into proliferation (European ISSX 2017)pdf
  • No. 17: Generation of expanded primary hepatocytes for cell based toxicity and metabolism screenings (European ISSX & Gordon Conference 2017)pdf
  • No. 18: Generation of expanded primary cells for cell-based toxicity and metabolism screenings (Safety & Pharmacology 2017)pdf
  • No. 19: Generation of proliferating human liver sinusoidal endothelial cells (upcyte® LSECs) (GASL 2018)pdf
  • No. 20: Generation of expanded primary hepatocytes for cell based toxicity and metabolism screenings (GASL 2018)pdf
  • No. 21: Facilitated genotoxicity screenings in expanded human upcyte® keratinocytes (SOT 2018)pdf
  • No. 22: Expanded primary human liver sinusoidal endothelial cells as a tool to complement hepatotoxicity studies (SOT2018)pdf
  • No. 23: Generation of Expanded Primary Cells for Cell-Based Toxicity andMetabolismScreenings (SLAS 2018)pdf
  • No. 24: Hepatobiliary transporter expression and functional uptake of substrates in 2D sandwich cultures using upcyte® hepatocytes (please refer to publication)
  • No. 25: Toxicity assays using expanded liver cells promote the reduction of animal use in pre-clinical research (Eurotox 2018)pdf
  • No. 26: Liver bud formation using human upcyte® cells (EUSAAT)pdf

 

Posters of our customers & partners

  • Kroener et al., Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (Stuttgart, Germany) - a multi-level approach to investigate CYP2D6 dependent metabolism of clomiphene (ISSX 2017)  pdf
  • Maalouf et al., Indigo Biosciences (State College, PA, USA) - Validating the gene expression of clinically relevant CYP450 enzymes and transporters in human upcyte® hepatocytes to develop an in vitro predictive tool for DDI (SOT 2017) pdf
  • Schaefer et al., Boehringer Ingelheim (Biberach, Germany) - Metabolic Capability of Upcyte® Human Hepatocytes in Long-Term Sandwich Culture and Utility for Clearance Prediction (ISSX Korea 2016) pdf
  • Schaefer et al. II, Boehringer Ingelheim (Biberach, Germany) - Comparison of Primary vs. Proliferative Human Hepatocytes in Long-Term Culture: Metabolic Capability and Usefulness for Clearance Prediction (ISSX Boston 2016) pdf
  • Bauer et al., Tissuse GmbH (Berlin, Germany) - Towards a multi-organ-chip combining human liver, pancreatic islets, skeletal muscle and kidney equivalenst to study metabolic diseases pdf

© 2018 by upcyte technologies GmbH // Osterfeldstrasse 12-14 // 22529 Hamburg // Germany